(CercleFinance.com) – Oddo BHF raises its opinion on Virbac from ‘neutral’ to ‘outperforming’ despite a price target reduced from 425 to 400 euros, after a publication for the first quarter of 2022 above expectations and accompanied by a raising annual targets.
‘Compared to Vétoquinol, Virbac must regain the ascendancy and reconstitute a premium’, judges the analyst who estimates that ‘if the valuation ratios of its peers have fallen significantly over the past six months, Virbac remains discounted (around 10%) ‘.
‘Contrary to what we could deduce from Vétoquinol’s figures for Europe, Virbac is recording a good level of growth, which deserves the stock to approach 395/400 euros in the short term,’ he continues.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
